Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144579 | 0.81 | CTSL (0.35) | MEN1MAPK1KMT2ACTSLAPLNR | |
| SCHEMBL15979063 | 0.81 | MEN1 (0.30) | MEN1MAPK1KMT2A | |
| SCHEMBL27213731 | 0.77 | — | — | |
| SCHEMBL15979029 | 0.77 | KMT2A (0.39) | MEN1MAPK1KMT2ACTSLFOLH1 | |
| SCHEMBL15979024 | 0.77 | MEN1 (0.39) | MEN1MAPK1KMT2ACTSLFOLH1 | |
| SCHEMBL23842466 | 0.76 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSLFOLH1 | |
| SCHEMBL27390294 | 0.76 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSLFOLH1 | |
| SCHEMBL15979034 | 0.75 | MEN1 (0.37) | MEN1MAPK1KMT2ACTSLFOLH1 | |
| SCHEMBL14476417 | 0.75 | TDP1 (0.39) | MEN1MAPK1KMT2ACTSLFOLH1 | |
| SCHEMBL14014440 | 0.74 | APLNR (0.34) | MEN1MAPK1KMT2ACTSLFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | MEN1 4182/4885MAPK1 3719/4885KMT2A 1081/4885 |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | HSD17B1, HSD17B3, HSD17B13 | MEN1 3752/4885MAPK1 2740/4885KMT2A 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.